Prevention of mother-to-child transmission of HIV - What next?

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 1, 2003, Pages

  Sullivan, John L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Antiretroviral therapy; HIV; Mother to child transmission; Pathogenesis; Prevention

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; ZIDOVUDINE;

BREAST FEEDING; BREAST MILK; CLINICAL TRIAL; CONFERENCE PAPER; DEVELOPING COUNTRY; ERADICATION THERAPY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NEWBORN; NEWBORN INFECTION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; VERTICAL TRANSMISSION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS RESISTANCE; VIRUS TRANSMISSION;

BREAST FEEDING; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0141569887     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309011-00010     Document Type: Conference Paper

References (30)

1. Mirochnick M, Fenton T, Gagnuir P, et al. Pharmacokinetics of nevirapine in HIV-1 infected pregnant women and their neonates. J Infect Dis 1998;178:368-374.
2. Gray G and McIntyre J. International AIDS Society Newsletter 1999;12:8-10.
3. Aleixo LF, Goodenow MM, Sleasman JW. Zidovudine administered to women infected with human immunodeficiency virus type 1 and to their neonates reduces pediatric infection independent of an effect on levels of maternal virus. J Pediatr 1997;130:906-914.
4. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal transmission of HIV-1 with zidovudine treatment. N Engl J Med 1994;331:1173-1180.
5. Fowler MG, Newell ML. Breast-feeding and HIV-1 transmission in resource-limited settings. JAIDS 2002;30:230-239.
6. Lackritz EM, Shaffer N, Luo C. Prevention of mother-to-child transmission in the context of a comprehensive AIDS agenda in resource-poor countries. JAIDS 2002;30:196-199.
7. Dabis F, Leroy V, Castetbon K, et al. Preventing mother-to-child transmission of HIV-1 in Africa in the year 2000. AIDS 2000;14:1017-1026.
8. Rouzioux C, Castgholia D, Burgod M, et al. Estimated timing of mother to child HIV-1 transmission by use of Markov model: the HIV infection in newborn. French Collaborative Study Group. Am J Epidemiol 1995;142:1330-1337.
9. Sperling RS, Shapiro DE, Coombs FW, et al. Maternal viral load, zidovudine treatment and risk of transmission of HIV from mother to child. N Engl J Med 1996;335:1621-1629.
10. Southern SO. Milk-borne transmission of HIV. J Human Virol 1998;1:328-337.
11. Lewis P, Nduati R, Kreiss JK, et al. Cell free HIV-1 in breast milk. J Infect Dis 1998;177:34-39.
12. Nduati R, Mbori-Ngacha D, Richardson B, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000;283:1167-1174.
13. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002;288:189-198.
14. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-1414.
15. International Perinatal HIV Group. Mode of delivery and risk of vertical transmission of HIV-1: a meta analysis of 15 prospective cohort studies. N Engl J Med 1999;340:977-987.
16. Musoke P, Guay L, Bagenda D, et al. A phase I and II study of the safety and pharmacokinetics of nevirapine in HIV-1 infection in pregnant Ugandan women and their neonates (HIVNET 0006) AIDS 1999;13:479-486.
17. Ioannidis J, Abrams E, Ammann A, et al. Perinatal transmission of HIV-1 by pregnant women with RNA virus load <1000 copies/mL. J Infect Dis 2001;183:539-545.
18. Centres for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR 1998;47:1-30.
19. UNAIDS/WHO AIDS Epidemic Update, December 1998. Available at: http://www.unaids.org/unaids/document/epidemio/wadr98e.pdf. Accessed 8 January 2002.
20. Lallemant M, Jourdain G, le Ceour S, et al. A trial of shortened zidovudine regimens to prevent mother to child transmission of HIV-1. Perinatal HIV prevention trial (Thailand) Investigators. N Engl J Med 2000;343:982-991.
21. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999;353:781-785.
22. Dabis F, Msellati P, Meda, et al. Six months efficacy and acceptability of a short regimen of oral ZDV to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso. Lancet 1999;353:786-792.
23. Gray G. The PETRA study: early and late efficacy of three short AZT/3TC combination regimens to prevent mother-to-child transmission of HIV-1 [abstract LbOr51]. Presented at the XIII International AIDS Conference, Durban, South Africa, 2000.
24. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa and Uganda (Petra study): a randomized, double-blind, placebo-controlled trial. Lancet 2002;359:1178-1186.
25. Guay LA, Musaka P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of women to child transmission of HIV-1 in Kampala, Uganda (HIVNET 012). Lancet 1999;354:795-802.
26. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003;187:725-35.
27. Nolan M, Fowler MG, Mofenson LM. Antiretroviral prophylaxis of perinatal HIV-1 transmission and potential impact of antiretroviral resistance. JAIDS 2002;30:216-229.
28. Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002;186:181-189.
29. Eshleman SH, Becker-Pergola G, Deseyve M, et al. Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 Study). J Infect Dis 2001;184:914-917.
30. Owor M, Deseyve M, Duefield C, et al. The one year safety study and efficacy data of the HIVNET 012 trial [abstract LBOr1]. Presented at the XIII International AIDS Conference, Durban, South Africa, 2000.